Noopur S. Raje

Noopur S. Raje, MD is Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. She is one of the world's leading experts in cellular immunotherapy for myeloma, most prominently as a key co-investigator and faculty lead for the KarMMa trial — the pivotal phase II study of idecabtagene vicleucel (ide-cel, bb2121), the first BCMA-directed CAR-T cell therapy, whose results published in NEJM (2021) demonstrated an ORR of 73% including 33% stringent CR in heavily pretreated, triple-class exposed patients, and led to FDA approval of ide-cel in March 2021. Dr. Raje has extensive expertise in translational myeloma biology, bone disease mechanisms in myeloma, and the development of novel immunotherapeutic approaches including BCMA-targeting bispecific antibodies such as teclistamab. Earlier in her career she made foundational contributions to understanding myeloma-induced bone destruction and the role of DKK1, RANKL, and osteoclast-activating factors — work that informed therapeutic strategies with denosumab and bisphosphonates. She has also been a principal investigator on multiple trials of elotuzumab, daratumumab combinations, and next-generation immunomodulatory approaches. Dr. Raje has authored over 300 peer-reviewed publications and serves on the ASH and ASCO program committees.